Tinnitus Week is taking place from 5-11 February 2018.
Auris Medical Holdings provided an update on the TACTT3 clinical trial with Keyzilen in the treatment of acute inner ear...
Auris Medical Holding AG announced top-line results from the Phase III TACTT2 trial with Keyzilen (AM 101) in acute inner...
AMPACT1 is the second of two open-label extension studies with Keyzilen that were conducted in response to a request from...
Auris Medical announced that it has developed a protocol for Phase II/III trial with Keyzilen / AM-101. The Company has...
Insmed Incorporated announced that data from the pivotal Phase III CONVERT study evaluating the safety and efficacy of ALIS (amikacin...
Otonomy, Inc., has announced that the Phase III clinical trial of Otividex (OTO 104) in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for Otividex vs. placebo for the intent-to-treat (ITT) population (n = 148; p value = 0.312) using the Negative Binomial Model.
Long-term management of chronic pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
For the treatment of hyperkeratotic and scaling conditions such as psoriasis.
As an aid in the removal of hardened ear wax.